Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966533 | 0.96 | XDH (0.45) | XDHS1PR2MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL23914602 | 0.85 | S1PR2 (0.41) | S1PR2MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL23908744 | 0.71 | S1PR2 (0.80) | S1PR2 | |
| SCHEMBL23909059 | 0.71 | S1PR2 (0.42) | XDHS1PR2 | |
| SCHEMBL23914853 | 0.69 | XDH (0.38) | XDH | |
| SCHEMBL23966834 | 0.69 | XDH (0.38) | XDH | |
| SCHEMBL22199021 | 0.65 | XDH (0.47) | XDH | |
| SCHEMBL23914653 | 0.65 | RHEB (0.41) | XDHS1PR2MAPTSMN1; SMN2 | |
| SCHEMBL9675828 | 0.65 | IDO1 (0.54) | MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL9675810 | 0.65 | MAPT (0.45) | MAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | XDH 3672/4885S1PR2 3/4885MAPT 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.